The U.S. Supreme Court has decline to hear argument over “objective falsehood” under the False Claims Act (FCA). This has been a hot button issue in litigation that has federal courts split and

Stephen Sheller, founder of Sheller P.C., and Eric Orts, Guardsmark Professor at the Wharton School at the University of Pennsylvania, penned a second request to the university’s administration for a formal investigation into allegations former President Trump

2020 Pennsylvania Trailblazers brought to you by The Legal Intelligencer Watch: Deadly Drugs – Johnson & Johnson’s Risperdal

With the Biden administration taking the White House last month, the new administration has been vocal about enforcing antitrust and fraud laws, especially as it pertains to those who took advance of federal

Last March federal prosecutors in Texas had a two-year investigation into Walmart’s questionable company policies for filling opioid prescriptions ended abruptly by Trump’s Department of Justice top officials just as prosecutors were ready

Two members of the Sackler family testified in front of Congress this month. David and Kathe Sackler both held executive positions and were active members on Purdue Pharma’s board during the time when

As U.S. prosecutors go through document in an attempt to hold drug companies, distributors, and pharmacies accountable to the part they played in the U.S. opioid epidemic, emails uncover another bad faith actor. Purdue

Purdue Pharma pleads guilty to criminal charges for illegal marketing of the its highly addictive painkiller, OxyContin. Corporations often pay penalties and fines for wrongdoing, yet criminal charges are rare. These charges include

The Pennsylvania Supreme Court has denied Johnson & Johnson’s request to overturn the $70 million Risperdal verdict upheld by a Superior court panel of judges last year. The case, A.Y. v. Janssen Pharmaceuticals,

As the COVID-19 pandemic continues to plague America, worsening the opioid crisis that has plagued the nation for decades, litigation to recoup the cost of fighting the opioid crisis has stalled. While local